Sign up to access all valuation multiples
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
1984
1.8K+
LTM Revenue $185M
LTM EBITDA $44.9M
$2.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Neuland Laboratories has a last 12-month revenue (LTM) of $185M and a last 12-month EBITDA of $44.9M.
In the most recent fiscal year, Neuland Laboratories achieved revenue of $164M and an EBITDA of $47.8M.
Neuland Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Neuland Laboratories valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $185M | XXX | $164M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $78.3M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 48% | XXX | XXX | XXX |
| EBITDA | $44.9M | XXX | $47.8M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 29% | XXX | XXX | XXX |
| EBIT | $39.5M | XXX | $30.5M | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $30.8M | XXX | $29.8M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 18% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $0.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 29, 2025, Neuland Laboratories's stock price is INR 13457 (or $154).
Neuland Laboratories has current market cap of INR 173B (or $2.0B), and EV of INR 171B (or $2.0B).
See Neuland Laboratories trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.0B | $2.0B | XXX | XXX | XXX | XXX | $2.26 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 29, 2025, Neuland Laboratories has market cap of $2.0B and EV of $2.0B.
Neuland Laboratories's trades at 11.7x EV/Revenue multiple, and 39.6x EV/EBITDA.
Equity research analysts estimate Neuland Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Neuland Laboratories has a P/E ratio of 64.2x.
See valuation multiples for Neuland Laboratories and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.0B | XXX | $2.0B | XXX | XXX | XXX |
| EV (current) | $2.0B | XXX | $2.0B | XXX | XXX | XXX |
| EV/Revenue | 10.6x | XXX | 11.7x | XXX | XXX | XXX |
| EV/EBITDA | 43.5x | XXX | 39.6x | XXX | XXX | XXX |
| EV/EBIT | 49.6x | XXX | 56.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 64.2x | XXX | 63.9x | XXX | XXX | XXX |
| EV/FCF | 232.5x | XXX | 151.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNeuland Laboratories's last 12 month revenue growth is 26%
Neuland Laboratories's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $27K for the same period.
Neuland Laboratories's rule of 40 is 55% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Neuland Laboratories's rule of X is 89% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Neuland Laboratories and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 26% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | 46% | XXX | 22% | XXX | XXX | XXX |
| Rule of 40 | 55% | XXX | 55% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 89% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $27K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Neuland Laboratories acquired XXX companies to date.
Last acquisition by Neuland Laboratories was XXXXXXXX, XXXXX XXXXX XXXXXX . Neuland Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Neuland Laboratories founded? | Neuland Laboratories was founded in 1984. |
| Where is Neuland Laboratories headquartered? | Neuland Laboratories is headquartered in India. |
| How many employees does Neuland Laboratories have? | As of today, Neuland Laboratories has 1.8K+ employees. |
| Who is the CEO of Neuland Laboratories? | Neuland Laboratories's CEO is Mr. Davuluri Sucheth Rao. |
| Is Neuland Laboratories publicy listed? | Yes, Neuland Laboratories is a public company listed on BOM. |
| What is the stock symbol of Neuland Laboratories? | Neuland Laboratories trades under 524558 ticker. |
| When did Neuland Laboratories go public? | Neuland Laboratories went public in 1994. |
| Who are competitors of Neuland Laboratories? | Similar companies to Neuland Laboratories include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Neuland Laboratories? | Neuland Laboratories's current market cap is $2.0B |
| What is the current revenue of Neuland Laboratories? | Neuland Laboratories's last 12 months revenue is $185M. |
| What is the current revenue growth of Neuland Laboratories? | Neuland Laboratories revenue growth (NTM/LTM) is 26%. |
| What is the current EV/Revenue multiple of Neuland Laboratories? | Current revenue multiple of Neuland Laboratories is 10.6x. |
| Is Neuland Laboratories profitable? | Yes, Neuland Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Neuland Laboratories? | Neuland Laboratories's last 12 months EBITDA is $44.9M. |
| What is Neuland Laboratories's EBITDA margin? | Neuland Laboratories's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Neuland Laboratories? | Current EBITDA multiple of Neuland Laboratories is 43.5x. |
| What is the current FCF of Neuland Laboratories? | Neuland Laboratories's last 12 months FCF is $8.4M. |
| What is Neuland Laboratories's FCF margin? | Neuland Laboratories's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Neuland Laboratories? | Current FCF multiple of Neuland Laboratories is 232.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
